The Next Wave For Melanoma
Executive Summary
Melanoma therapy could take another leap forward with the development of another BRAF inhibitor, a MEK inhibitor, and late-stage trials testing combinations against both BRAF options alone.
You may also be interested in...
Genentech Catching Up In Melanoma With Cotellic Approval
FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.
GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
In the COMBI-v study, BRAF/MEK combination Tafinlar/Mekinist improves overall survival by 31% compared to BRAF monotherapy. GSK’s combination and Genentech’s cobimetinib/Zelboraf combination both improve progression-free survival and reduce cutaneous malignancies compared to monotherapy.
GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
In the COMBI-v study, BRAF/MEK combination Tafinlar/Mekinist improves overall survival by 31% compared to BRAF monotherapy. GSK’s combination and Genentech’s cobimetinib/Zelboraf combination both improve progression-free survival and reduce cutaneous malignancies compared to monotherapy.